Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe | Zendy

Odile Launay | Zendy; David Lewis | Zendy; Alessandra Anemona | Zendy; Pierre Loulergue | Zendy; Jo Leahy | Zendy; Antonella Silvia Sciré | Zendy; Anaïs Maugard | Zendy; Elisa Marchetti | Zendy; Stefano Zancan | Zendy; Zhiming Huo | Zendy; Simona Rondini | Zendy; Rachid Marhaba | Zendy; Oretta Finco | Zendy; Laura B. Martin | Zendy; Jochen Auerbach | Zendy; Dani Cohen | Zendy; Allan Saul | Zendy; Christiane Gerke | Zendy; Audino Podda | Zendy

Open Access

Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe

Author(s) -

Odile Launay,

David Lewis,

Alessandra Anemona,

Pierre Loulergue,

Jo Leahy,

Antonella Silvia Sciré,

Anaïs Maugard,

Elisa Marchetti,

Stefano Zancan,

Zhiming Huo,

Simona Rondini,

Rachid Marhaba,

Oretta Finco,

Laura B. Martin,

Jochen Auerbach,

Dani Cohen,

Allan Saul,

Christiane Gerke,

Audino Podda

Publication year - 2017

Publication title -

ebiomedicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.596

H-Index - 63

ISSN - 2352-3964

DOI - 10.1016/j.ebiom.2017.07.013

Subject(s) - shigella sonnei , immunogenicity , shigellosis , medicine , placebo , nasal administration , immunology , virology , shigella , population , intramuscular injection , vaccination , antigen , biology , environmental health , salmonella , genetics , alternative medicine , pathology , bacteria

Approximately 164,000 deaths yearly are due to shigellosis, primarily in developing countries. Thus, a safe and affordable Shigella vaccine is an important public health priority. The GSK Vaccines Institute for Global Health (GVGH) developed a candidate Shigella sonnei vaccine (1790GAHB) using the Generalized Modules for Membrane Antigens (GMMA) technology. The paper reports results of 1790GAHB Phase 1 studies in healthy European adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research